J3300 HCPCS code: Injection, triamcinolone acetonide (triesence), preservative free, 1 mg
J3300 is the HCPCS Level II code for injection, triamcinolone acetonide (triesence), preservative free, 1 mg. In 2024 Medicare paid an average of $3.54 per service for J3300 across 798,270 services. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met. The NCCI unit limit is 80 per day on outpatient hospital claims. Medicare volume fell 63% from 2022 to 2024 (2,154,478 to 798,270 services). In 2024, about 595 clinicians billed Medicare for J3300 for 11,356 beneficiaries; Virginia, Florida, New Jersey accounted for 59% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2009-01-01 |
| Last action effective | 2026-10-01 |
Who bills J3300 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 595 |
| Medicare beneficiaries | 11,356 |
| States with claims | 31 |
| Share of services in top 3 states (Virginia, Florida, New Jersey) | 59% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J3300, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 2,154,478 | 23,993 | $3.77 | $2.98 |
| 2023 | 1,202,707 | 19,741 | $3.97 | $3.13 |
| 2024 | 798,270 | 11,356 | $4.45 | $3.54 |
States with the most J3300 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Virginia | 173,436 | $0.58 |
| Florida | 152,196 | $5.85 |
| New Jersey | 147,896 | $3.98 |
| North Carolina | 59,264 | $0.45 |
| New York | 38,660 | $3.77 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 80 | CMS Policy |
| practitioner claims | 80 | CMS Policy |
Medicare policy articles for this code
- A57114: Billing and Coding: Trigger Point Injections (First Coast Service Options, Inc. (MAC - Part B))
- A57751: Billing and Coding: Trigger Point Injections (Novitas Solutions, Inc. (MAC - Part A, MAC - Part B))
Covered diagnoses (2 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| M79.12 | Myalgia of auxiliary muscles, head and neck | 2 |
| M79.18 | Myalgia, other site | 2 |
What changed for J3300
- October 2026: Descriptor revised (Was: Injection, triamcinolone acetonide, preservative free, 1 mg)
- 2026-10-01: Last CMS action: long description changed
- 2009-01-01: J3300 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J3300?
J3300 is the HCPCS Level II code for injection, triamcinolone acetonide (triesence), preservative free, 1 mg. Short descriptor: "Triamcinolone a inj prs-free".
How much does Medicare pay for J3300?
In 2024, the average Medicare payment was $3.54 per service (average allowed $4.45).
Does Medicare cover J3300?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
Which diagnoses support coverage for J3300?
Medicare policy articles that cite J3300 list 2 covered ICD-10-CM diagnosis codes across 2 articles. The most cited include M79.12 (Myalgia of auxiliary muscles, head and neck), M79.18 (Myalgia, other site). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J3300 can be billed per day?
80 on outpatient hospital claims; 80 on practitioner claims (NCCI medically unlikely edits).
Related J33 codes
- J3301 — Injection, triamcinolone acetonide, not otherwise specified, 10 mg
- J3302 — Injection, triamcinolone diacetate, per 5 mg
- J3303 — Injection, triamcinolone hexacetonide, per 5 mg
- J3304 — Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
- J3305 — Injection, trimetrexate glucuronate, per 25 mg
- J3310 — Injection, perphenazine, up to 5 mg
- J3315 — Injection, triptorelin pamoate, 3.75 mg
- J3316 — Injection, triptorelin, extended-release, 3.75 mg
- J3320 — Injection, spectinomycin dihydrochloride, up to 2 gm
- J3350 — Injection, urea, up to 40 gm
- J3355 — Injection, urofollitropin, 75 iu
- J3357 — Ustekinumab, for subcutaneous injection, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J3300
- Watch J3300 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J3300
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.